Biosimilars A slew of regulatory reforms is in the offing for the biotech industry in India, with the government seeking to accelerate biologics and biosimilar development in the country. Apart from an amendment to Guidelines on Similar Biologics, the industry is to get the benefit of certain measures that will facilitate commercial stockpiling of biosimilar products before issuance of marketing authorization in order to propel their launch in the market in line with the US Food and Drug Administration, reports The Pharma Letter’s India correspondent. 19 October 2021